An Active Surveillance, Post Authorization Safety Study (PASS) of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among Patients Treated with Tofacitinib for Moderately to Severely Active Rheumatoid Arthritis (RA) within the German Registry Rheumatoide Arthritis: Beobachtung der Biologika Therapie (RABBIT) (Safety of tofacitinib in RABBIT)

05/09/2019
02/07/2024
EU PAS number:
EUPAS31164
Study
Ongoing
Documents
Study protocol
Initial protocol
English (1.56 MB - PDF) View document
Updated protocol
English (377.9 KB - PDF) View document
Study results
Study report
Other information
Study, other information
English (558.7 KB - PDF) View document